Ni Xiong

Dr. Ni Xiong


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
莉尹莉慧 尹
莉慧 尹
XWXuehua Wang
Xuehua Wang
NXNi Xiong
Ni Xiong
JXJinjie Xiong
Jinjie Xiong
QLQianyi Liu
Qianyi Liu
ZWZhaohui Wang
Zhaohui Wang
Atherosclerosis (AS) is a disease characterized by chronic vascular wall inflammation and lipid deposition. Although lipid-lowering drugs such as statins have significantly reduced cardiovascular event rates, “residual inflammatory risk” remains a key factor driving disease progression and plaque rupture. As a central regulator of the inflammatory response, the nuclear factor-κappaB (NF-κB) signaling network comprises both canonical pro-inflammatory pathways and functionally more complex non-canonical pathways. Increasing evidence in recent years indicates that abnormal and sustained activation of the non-canonical NF-κB signaling pathway plays a pivotal role in driving plaque rupture. This review first elaborates on the shift in AS strategies from “lipid-lowering” to “anti-inflammatory” approaches, followed by an in-depth analysis of the molecular activation mechanisms of the NF-κB signaling pathway and its distinctiveness in the AS pathological process, along with its epigenetic regulation. It emphasizes how this pathway drives pathological angiogenesis and regulates vascular smooth muscle cell (VSMC) phenotypic switching and macrophage function, thereby forming a vicious cycle that amplifies inflammation and structural damage, ultimately leading to acute cardiovascular events. Finally, we systematically summarize current progress and challenges in drug development targeting the NF-κB pathway (e.g., targeting key kinases like NIK and IKKα), aiming to provide theoretical foundations and future directions for novel therapeutic strategies to stabilize coronary plaques and prevent acute coronary syndromes.

19 November 2025 in Bioengineering
Verified
Journal Article
Open access
PDF file
NXNi Xiong
Ni Xiong
ZWZibo Wei
Zibo Wei
XWXuehua Wang
Xuehua Wang
YWYan Wang
Yan Wang
ZWZhaohui Wang
Zhaohui Wang
Accurate detection of cardiac arrhythmias from electrocardiogram (ECG) signals is essential for the early diagnosis of cardiovascular diseases but remains challenging due to the complex, non-linear nature of ECG waveforms. This study proposes HCTG-Net, a Hybrid CNN–Transformer Network with Gated Fusion, designed to jointly capture local morphological features and long-range temporal dependencies in ECG data. The model employs a dual-branch architecture, where a residual CNN extracts localized waveform patterns and a Transformer branch models global temporal context. A learnable gated fusion mechanism adaptively balances and integrates features from both branches at the per-dimension level. Experiments conducted on the MIT-BIH Arrhythmia Database demonstrate that HCTG-Net achieves superior performance compared with existing methods, reaching an overall accuracy of 0.9946 and F1-score of 0.9711. Visualization results show well-clustered feature distributions, confirming robust feature learning, while ablation studies verify the complementary roles of the CNN, Transformer, and fusion modules. Overall, HCTG-Net offers a powerful and adaptive framework for automatic ECG-based arrhythmia diagnosis and holds strong potential for real-time clinical and wearable healthcare applications.

30 December 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
YHYanling Huang
Yanling Huang
HLHan Li
Han Li
JXJinjie Xiong
Jinjie Xiong
XWXvehua Wang
Xvehua Wang
JLJiaxi Lv
Jiaxi Lv
YWYan Wang
Yan Wang
Ischemic heart disease remains the leading cause of cardiovascular mortality worldwide. In myocardial infarction (MI), extracellular vesicles (EVs)—particularly small EVs (sEVs)—transport therapeutic cargo such as miR-21-5p, which suppresses apoptosis, and other proteins, lipids, and RNAs that can modulate cell death, inflammation, angiogenesis, and remodeling. This review synthesizes recent mechanistic and preclinical evidence on native and engineered EVs for post-MI repair, mapping therapeutic entry points across the MI timeline (acute injury, inflammation, and healing) and comparing EV sources (stem-cell and non-stem-cell), administration routes, and dosing strategies. We highlight engineering approaches—including surface ligands for cardiac homing, rational cargo loading to enhance potency, and biomaterial depots to prolong myocardial residence—that aim to improve tropism, durability, and efficacy. Manufacturing and analytical considerations are discussed in the context of contemporary guidance, with emphasis on identity, purity, and potency assays, as well as safety, immunogenicity, and pharmacology relevant to cardiac populations. Across small- and large-animal models, EV-based interventions have been associated with reduced infarct/scar burden, enhanced vascularization, and improved ventricular function, with representative preclinical studies reporting approximately 25–45% relative reductions in infarct size in rodent and porcine MI models, despite substantial heterogeneity in EV sources, formulations, and outcome reporting that limits cross-study comparability. We conclude that achieving clinical translation will require standardized cardiac-targeting strategies, validated good manufacturing practice (GMP)-compatible manufacturing platforms, and harmonized potency assays, alongside rigorous, head-to-head preclinical designs, to advance EV-based cardiorepair toward clinical testing.